Drug intelligence / Profile preview

Doxefazepam

Development stage: Discontinued
Lead developer: Schiapparelli Farmaceutici
Modality: Small Molecules
Administration: Oral

Overview

Doxefazepam is a small molecule benzodiazepine derivative that possesses anxiolytic, anticonvulsant, sedative, and skeletal muscle relaxant properties. It was primarily used therapeutically as a hypnotic for the short-term management of insomnia. Developed by Schiapparelli in the 1970s, it was patented in 1972 and entered medical use in 1984. Doxefazepam was approved for use in Italy from the mid-1980s until 1995, when it was discontinued and no longer available for purchase.

Brand names: Doxans
Other names: N-1-Hydroxyethyl-3-hydroxyflurazepamN1-Hydroxyethyl-3-hydroxyflurazepamN 1-Hydroxyethyl-3-hydroxyflurazepam

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on Doxefazepam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Doxefazepam.

Explore the full profile